Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02156115 · ClinicalTrials.gov registry record
Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- 14
- Enrollment target
NCT02156115: Clinical Trial study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT02156115 is a clinical trial that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02156115 was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
Background: \- Lymphatics are a type of vessel, similar to arteries and veins. Lymphatic disorders happen when these vessels don t work properly. Researchers want to look for a relationship between lymphatic disorders and variations of certain genes found in the lung, blood, and other places in the body. Objective: \- To learn more about lymphatic disorders and evaluate how genetic factors affect lymphatic disorders. Eligibility: * People ages 2 90 who have a lymphatic disorder or relatives of people with lymphatic disorders. * Healthy volunteers 18 and older. Design: * Participants may have 1 2 visits a year, or more as needed. The study is expected to last 5 years. Visits may last 1 5 days. Participants may have lab tests, medical history, and physical exam at each visit. * Participants may have blood testing that includes genetics tests, and urine tests. They may have nose and throat cultures, saliva collection, and cheek swabs to collect samples. * Participants may have a skin biopsy and have blood taken from an artery. * Participants may have breathing tests and be studied while exercising. * Participants may have an electrocardiogram. Electrodes will be placed on their chest, tracing heart rhythms. They may also have chest X-rays. * Participants may have a bronchoscopy. A thin, flexible instrument will be passed through the nose or mouth, into the lung. A tissue sample will be taken. * Participants who have lymphatic disease or have a relative with it may also have: * CT scans. They will lie on a table and hold their breath while their chest is scanned. * MRI. They will lie flat on a table that slides in and out of a scanner. * ultrasound. A probe is rolled around outside the abdomen. * removal of fluid around the lungs, chest, and abdomen.
Primary Outcome
To define the clinical phenotype of the lymphatic disorder.To define the molecular basis of the lymphatic disorders.This knowledge will help in improving our understanding of lymphatic proliferation in normal conditions as well as in disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-03-23 |
| Est. Completion | 2024-04-01 |
Why NCT02156115 stopped before completion
NCT02156115 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02156115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02156115 about?
NCT02156115 is a clinical study titled "Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders". Background: \- Lymphatics are a type of vessel, similar to arteries and veins. Lymphatic disorders happen when these vessels don t work properly. Researchers want to look for a relationship between lymphatic disorders and variations of certain genes found in the lung, blood, and other places in the...
What is the current status of trial NCT02156115?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2015-03-23. Estimated completion is 2024-04-01.
Who is sponsoring clinical trial NCT02156115?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy